The percentage of high DOT1L expression was 14.6% in normal ovarian tissues, 23.4% in benign ovarian tumors, 21.5% in borderline ovarian tumors, and increased to 57.5% in malignant ovarian tumors (normal vs. malignant, P < 0.0001; benign vs. malignant, P = 0.012; borderline vs. malignant, P = 0.082; normal vs. benign, P = 0.69; normal vs. borderline, P = 0.62; benign vs. borderline, P = 1.00) (Fig. 1b). This evidence concerns the gene DOT1L and ovarian cancer.